VEGFR2 is expressed by tumor cells and targeting this receptor may simultaneously affect tumor stroma (i.e. blood vessels) and tumor parenchyma, as it has been demonstrated in a variety of tumor types, including NSCLC [8]. This evidence concerns the gene KDR and neoplasm.